GLP-1 analogs and inhibitors of dipeptidyl peptidase 4 (DPP4)—an enzyme responsible for incretin degradation—were registered for T2D treatment over a decade ago. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.